GEPATOTOKSIK DORILAR (AMIODARON, ISONIAZID, RIFAMPITSIN) VA ULARNI XAVFSIZ QO'LLASH STRATEGIYASI
Authors/Creators
- 1. Samarqand davlat tibbiyot universiteti, 2-son Davolash ishi fakultetining 5-bosqich talabasi.
- 2. Samarqand davlat tibbiyot universiteti, Tibbiy profilaktika, jamoat salomatligi va tibbiy biologiya fakulteti 2-kurs talabasi.
- 3. Samarqand davlat tibbiyot universiteti, 1-son ichki kasalliklar kafedrasi dotsenti, PhD Samarqand, O'zbekiston
Description
Gepatotoksik dorilar — klinik amaliyotda keng qo‘llaniladigan, ammo jigar faoliyatiga salbiy ta’sir ko‘rsatishi mumkin bo‘lgan farmakologik vositalar hisoblanadi. Ular orasida Amiodaron, Isoniazid va Rifampitsin ayniqsa alohida o‘rin tutadi. Ushbu maqolada ushbu dorilarning gepatotoksiklik mexanizmlari, xavf omillari va klinik ko‘rinishlari chuqur tahlil qilinadi. Amiodaronning lipidlarda eruvchanligi va jigar to‘qimalarida to‘planish xususiyati uning sekin rivojlanadigan, ammo potensial xavfli gepatotoksik ta’sirini keltirib chiqaradi. Isoniazid esa silga qarshi birinchi qatordagi dori sifatida yuqori terapevtik ahamiyatga ega bo‘lsa-da, genetik, yoshga oid va yondosh kasalliklar bilan bog‘liq risklar sababli gepatitga olib kelishi mumkin. Rifampitsin esa ferment induktorligi orqali boshqa dorilarning metabolizmini o‘zgartirib, gepatotoksiklik xavfini yanada oshiradi. Maqolada ushbu dorilarning xavfsiz qo‘llanishi uchun zarur bo‘lgan profilaktik chora-tadbirlar, laborator monitoringning roli, individual yondashuv va gepatoprotektiv vositalar qo‘llanilishi bo‘yicha ilmiy asoslangan strategiyalar yoritilgan. Tadqiqot natijalari shuni ko‘rsatadiki, ushbu dori vositalarini ratsional va nazorat ostida qo‘llash orqali ularning salbiy ta’sirlarini minimal darajaga tushirish mumkin
Files
220_228_Fazliddinov_Janobiddin_Zaynobiddin_o‘g‘li_Pardayev_Musobek.pdf
Files
(919.2 kB)
| Name | Size | Download all |
|---|---|---|
|
md5:b787455427d771011a8b02b77990d1cc
|
919.2 kB | Preview Download |
Additional details
References
- 1. Björnsson, E. S. (2016). Hepatotoxicity by drugs: the most common implicated agents. International Journal of Molecular Sciences, 17(2), 224. https://doi.org/10.3390/ijms17020224
- 2. Kaplowitz, N. (2005). Drug-induced liver injury. Clinical Infectious Diseases, 41(Supplement_5), S44-S48. https://doi.org/10.1086/430954
- 3. Tujios, S., & Lee, W. M. (2017). Acute liver failure induced by drugs: clinical features, diagnosis, and management. Clinics in Liver Disease, 21(3), 573-586. https://doi.org/10.1016/j.cld.2017.03.006
- 4. Rentsch, K. M., et al. (2017). Risk of liver toxicity in patients treated with amiodarone: A systematic review. Drug Safety, 40(3), 233-242. https://doi.org/10.1007/s40264-016-0482-4
- 5. Saukkonen, J. J., et al. (2006). An official ATS statement: hepatotoxicity of antituberculosis therapy. American Journal of Respiratory and Critical Care Medicine, 174(8), 935-952. https://doi.org/10.1164/rccm.200510-1666ST